Biocept (BIOC +15.2%) and Aegea Biotechnologies agree to develop a highly sensitive PCR-based assay designed by Aegea for detecting the COVID-19 virus.
The collaboration will leverage Biocept’s experience in developing high-performance assays based on the Switch-Blocker technology.
“This agreement provides Biocept with new incremental revenue for R&D development services and, if successfully developed, an option to expand our COVID-19 testing capabilities with a next-generation COVID-19 PCR assay, having competitive advantages.” said Michael Nall, President and CEO of Biocept.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.